Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Binger Str. 173 , Ingelheim, 55216, DE
The collaboration leverages Rectify’s PFM platform to develop oral, small molecules that enhance ABCC6 protein function and reduce calcification.
By: Charlie Sternberg
CDR111 is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.
Aligns with Boehringer’s strategy to develop cancer cell–directed and immuno-oncology therapies.
Aim to identify novel antibody sequences that may be difficult to discover using conventional methods.
Anagnostopoulos will lead the advancement of Valo’s human causal biology platform.
Filosi’s leadership experience includes major pharma companies including Merck KGaA, Boehringer Ingelheim, and Johnson & Johnson.
By: Patrick Lavery
Back has held senior scientific and leadership roles at Orion Pharma and Charles River.
Josh Ofman to serve as CEO following Bob Ragusa’s retirement in June.
The program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells.
PAI took place over four days for an API that the Malvern, PA site will manufacture for a global pharma company.
By: Kristin Brooks
Following a prior Refusal-to-File and Type A meeting, the FDA's CBER will proceed to review BLA for mRNA-1010.
Keefe has 30 years of experience in finance, accounting and operations in the life sciences.
The Data-as-a-Service technology will act as an accelerator for Boehringer Ingelheim’s global commercial data harmonization efforts.
The agreement is to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody developed by Simcere.
Amgen, BMS, Boehringer Ingelheim, GSK and more agree to lower the cost of medicines for Americans in line with the lowest prices paid by other developed nations.
Will evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
